Hypercalcemia of Malignancy

Hypercalcemia of malignancy (HCM) is a paraneoplastic syndrome defined by elevated serum calcium resulting from a tumor. Also known as malignancy-associated hypercalcemia or paraneoplastic hypercalcemia, it is the second most common cause of hypercalcemia after primary hyperparathyroidism , together accounting for 90% of cases ^[8]D5. The clinical significance stems from its potential for life-threatening metabolic derangement and its role as a marker of advanced disease.

Classification by Pathophysiology

HCM is classified into four subtypes based on the underlying mechanism, each with distinct therapeutic implications. The most common is humoral hypercalcemia of malignancy (HHM), driven by tumor secretion of parathyroid hormone-related protein (PTHrP). PTHrP shares high sequence homology with parathyroid hormone (PTH) and activates the same receptor (PTH1R) in bone and kidney, causing increased bone resorption and renal calcium reabsorption ^[1]B2a[7]D5. This subtype is typically associated with solid tumors, including breast, gynecologic, and squamous cell carcinomas ^[1]B2a[5]D5.

Osteolytic hypercalcemia results from local bone resorption mediated by metastases, most classically in multiple myeloma, where bone demineralization is a hallmark ^[6]D5. Vitamin D-mediated hypercalcemia is due to extrarenal production of 1,25-dihydroxyvitamin D (calcitriol) by tumor cells expressing 25-hydroxyvitamin D3-1α-hydroxylase, as reported in gastrointestinal stromal tumors (GIST) and certain solid organ malignancies ^[2]C4[4]C4. A fourth subtype, ectopic PTH secretion, is extremely rare and not discussed further here.

Severity Grading

Hypercalcemia is conventionally graded as mild (serum calcium 10.5-11.9 mg/dL), moderate (12-13.9 mg/dL), or severe (≥14 mg/dL). Grading influences the urgency of intervention, though management is driven more by symptoms and rate of rise than by the absolute number.

Rationale for Classification

Identifying the subtype is critical because treatment differs: HHM responds to bisphosphonates and denosumab, while vitamin D-mediated hypercalcemia may require glucocorticoids to suppress calcitriol production. The epidemiology of each subtype varies by tumor type, a topic explored in the next section.

Pearl: Subtype classification guides treatment selection, particularly the use of glucocorticoids for calcitriol-mediated hypercalcemia.

Following the classification of hypercalcemia of malignancy (HCM) into humoral, osteolytic, and other mechanisms, its epidemiology reflects the frequency and distribution of the underlying cancers. Among patients presenting to the emergency department with severe hypercalcemia (≥2.80 mmol/L), malignancy is the most common identifiable cause, accounting for 40% of cases ^[14]B2b. The overall prevalence of hypercalcemia (≥2.60 mmol/L) in the same tested population was 2.7% ^[14]B2b.

Cancer Types and Incidence

Lung cancer is the most frequent malignancy associated with HCM, representing 20% of malignancy-related severe hypercalcemia, followed by multiple myeloma (14%) and renal cell carcinoma (11%) ^[14]B2b. In a case series of HCM presenting with acute pancreatitis, parathyroid carcinoma and multiple myeloma each accounted for 21.6% of cases, with a mean corrected calcium of 14.5 mg/dL ^[12]C4. Osteolytic bone disease is present in 70% of patients with multiple myeloma, and hypercalcemia commonly results from bone demineralization ^[6]D5. Metastatic bone disease occurs in 20% to 40% of patients with lung cancer, and skeletal-related events (SREs) including hypercalcemia are frequent ^[9]A1a. Up to 17% of patients with melanoma develop metastatic bone disease, and 52% experience an SRE within 1 year of diagnosis ^[10]B2b. Among patients with Ewing sarcoma, the SRE-free rate was 94.2% at 1 year, 87.3% at 2 years, and 79.6% at 3 years; hypercalcemia as an initial SRE was rare (4.3%) ^[11]B2b.

Risk Factors

Risk factors for SREs that include hypercalcemia have been identified in several cancer types. The table below summarizes factors associated with SRE risk from available studies.

Parathyroid hormone-related protein (PTHrP) expression in breast cancer is associated with lymph node invasion and bone metastases, but its role as an independent risk factor for HCM remains uncertain due to high risk of bias in available studies ^[1]B2a.

Demographic and Temporal Trends

Available data do not provide robust age- or sex-specific incidence rates for HCM. The mean age of patients with HCM and acute pancreatitis was 44.8 years ^[12]C4. No temporal trends in HCM incidence were reported in the reviewed evidence. Seasonal variation has not been described.

Pearl: In patients with severe hypercalcemia, malignancy is the underlying cause in 40% of cases; lung cancer, multiple myeloma, and renal cell carcinoma are the most frequent culprits, warranting a focused diagnostic workup for these cancers ^[14]B2b.

Beyond incidence, the mechanistic underpinnings of hypercalcemia of malignancy fall into two dominant patterns: humoral hypercalcemia driven by parathyroid hormone-related protein (PTHrP) and local osteolytic hypercalcemia from direct bone destruction. A third, rarer mechanism involves ectopic 1,25-dihydroxyvitamin D production, though the provided evidence does not support a detailed discussion of that or of ectopic PTH secretion.

Humoral Hypercalcemia of Malignancy (HHM)

HHM accounts for approximately 80% of cases and is mediated by tumor-secreted PTHrP. PTHrP binds to the same receptor as parathyroid hormone, the PTH/PTHrP receptor (PTH1R), which is abundantly expressed on osteoblasts and stromal cells in bone ^[16]D5. This binding stimulates osteoblasts to increase expression of receptor activator of nuclear factor kappa-B ligand (RANKL) while suppressing osteoprotegerin (OPG), shifting the RANKL/OPG ratio in favor of osteoclastogenesis ^[16]D5[24]D5. The resulting osteoclast activation drives bone resorption, releasing calcium and phosphate into the circulation.

In breast cancer, which frequently causes HHM, 90% of bone metastases express PTHrP, compared with only 50% of primary tumors ^[24]D5. This upregulation underscores the critical role of PTHrP in skeletal tropism and the establishment of a vicious cycle: tumor-derived PTHrP → osteoblast RANKL → osteoclast activation → bone resorption releases growth factors (TGF-β, IGFs) that further stimulate tumor cell proliferation and PTHrP secretion ^[16]D5. This cycle perpetuates progressive bone loss and hypercalcemia. PTHrP also acts on the renal tubule (via the same receptor) to increase calcium reabsorption and phosphate excretion, compounding the elevation in serum calcium, though this effect is not explicitly detailed in the cited abstracts.

Local Osteolytic Hypercalcemia (LOH)

LOH occurs when tumor cells directly infiltrate the bone marrow and secrete factors that activate osteoclasts locally. This mechanism is common in multiple myeloma , breast cancer, and lung cancer. The RANK/RANKL/OPG axis is central: tumor cells or surrounding stromal cells produce RANKL (or induce its expression), while OPG levels decline, allowing unchecked osteoclast activation ^[24]D5. Additionally, tumor-derived factors such as interleukin-6, tumor necrosis factor, and prostaglandin E2 can directly stimulate osteoclastogenesis ^[16]D5.

Osteoclasts resorb bone by secreting cathepsin K and matrix metalloproteinases (MMPs), particularly MMP-9, which degrade the bone matrix and release growth factors that further feed tumor growth ^[24]D5. The structural weakening of bone leads to pathological fractures, which can themselves increase calcium release. Multiple myeloma, though not covered in the provided references, is a classic example of LOH driven by osteoclast-activating cytokines.

The RANKL/OPG Axis and the Vicious Cycle

Both HHM and LOH converge on the RANKL/OPG axis. The following flowchart illustrates the cascade:

The vicious cycle is a key therapeutic target. Denosumab, a monoclonal antibody against RANKL, blocks this axis and reduces skeletal-related events, including hypercalcemia ^[24]D5. Bisphosphonates inhibit osteoclast function and are also effective, though they do not directly target RANKL ^[24]D5.

Other Cytokines and Mediators

Beyond PTHrP and RANKL, tumor cells produce a milieu of cytokines, including IL-6, TNF-α, and macrophage colony-stimulating factor, that enhance osteoclast formation and activity ^[16]D5[24]D5. In breast cancer, the glycoprotein SCUBE2 activates Hedgehog signaling in mesenchymal stem cells, inducing osteoblast differentiation and collagen secretion, which then suppresses natural killer cell activity, facilitating immune evasion within the bone niche ^[16]D5. This immune-privileged environment further supports tumor growth and bone destruction.

Pearl: In any patient with hypercalcemia and a known malignancy, an elevated PTHrP level confirms humoral hypercalcemia, while a suppressed PTHrP with elevated bone turnover markers points to local osteolytic disease. Both mechanisms ultimately converge on the RANKL/OPG axis, making RANKL inhibition a cornerstone of therapy.

From the pathophysiologic pathways described above, the clinical expression of hypercalcemia of malignancy ranges from an incidentally detected laboratory abnormality to a life-threatening metabolic crisis. The severity of symptoms correlates with the corrected serum calcium level and, perhaps more importantly, the rate of rise, a rapid increase over days can overwhelm compensatory mechanisms and produce florid symptoms at calcium levels that might be tolerated if they developed over weeks.

Presenting Symptoms

More than half of patients with severe hypercalcemia (corrected calcium ≥3.0 mmol/L) present with acute neuropsychiatric or gastrointestinal complaints ^[14]B2b. In a recent emergency department cohort, neuropsychiatric symptoms were reported in 35% of patients and gastrointestinal symptoms in 24% ^[14]B2b. Malignancy was the underlying cause in 40% of cases, most commonly lung cancer (20%), multiple myeloma (14%), and renal cell carcinoma (11%) ^[14]B2b.

• Neurologic: confusion, lethargy, disorientation, drowsiness, muscle weakness, and, in severe cases, stupor or coma. Deep tendon reflexes may be diminished.
• Gastrointestinal: anorexia, nausea, vomiting, constipation, and abdominal pain. Ileus can occur with very high calcium levels.
• Renal: polyuria and polydipsia from impaired renal concentrating ability (nephrogenic diabetes insipidus), leading to volume depletion, which further impairs calcium excretion and worsens hypercalcemia.
• Cardiovascular: shortened QT interval, bradyarrhythmias, and, rarely, ventricular arrhythmias . Hypotension can occur from volume depletion.

Constitutional symptoms, fatigue, malaise, and weight loss, are common but often attributed to the underlying malignancy itself, delaying recognition.

Severity Grading

A practical clinical classification uses the corrected calcium (calcium adjusted for albumin):

Note: Ionized calcium may be more reliable in critically ill patients with hypoalbuminemia; a corrected calcium >3.0 mmol/L in a cancer patient warrants urgent intervention.

Neurological Examination Findings

The neurological examination in severe hypercalcemia reveals a global encephalopathy without focal signs. The patient appears drowsy, confused, or obtunded. Cranial nerve functions are intact unless the patient is too obtunded to cooperate. Motor examination shows diffuse hypotonia and proximal muscle weakness; reflexes are hypoactive or absent. Autonomic instability is uncommon but can manifest as orthostatic hypotension from volume depletion. A key teaching point: focal neurologic deficits should prompt a search for brain metastases rather than be attributed to hypercalcemia alone.

Pediatric Considerations

Hypercalcemia of malignancy in children is rare (<1% of pediatric cancers) and is most often associated with acute lymphoblastic leukemia (ALL) ^[30]D5. The clinical presentation mirrors that in adults, confusion, vomiting, constipation, but can be mistaken for a viral illness. A high index of suspicion in a child with known malignancy and subtle neurologic or gastrointestinal symptoms is essential ^[30]D5.

Atypical Presentations

Occasionally, hypercalcemia of malignancy presents with isolated renal colic from calcium-containing stones, mimicking primary hyperparathyroidism . In patients with ectopic PTHrP secretion (e.g., from squamous cell lung cancer), the clinical picture may be dominated by severe hypophosphatemia and renal phosphate wasting, which can exacerbate muscle weakness. Up to 38% of cases of severe hypercalcemia are not mentioned in the final discharge report, highlighting the need for clinical vigilance ^[14]B2b.

Pearl: In a cancer patient with new-onset confusion, always check a calcium, it is a rapidly reversible cause of encephalopathy. The severity of symptoms often correlates better with the rate of rise than the absolute calcium level; a slow climb to 3.2 mmol/L may be asymptomatic, whereas a jump to 3.0 mmol/L over 48 hours can produce obtundation.

Once hypercalcemia is suspected from the clinical picture, the diagnostic workup proceeds in a structured sequence to confirm the diagnosis, identify the subtype, and exclude alternative causes. The cornerstone is a panel of serum and urine tests interpreted in the context of the patient's malignancy status.

Laboratory Studies

Corrected serum calcium is the initial screening test. The formula corrects for albumin: corrected Ca (mg/dL) = measured total Ca + 0.8 × (4.0 - albumin in g/dL). A corrected calcium ≥10.5 mg/dL (2.6 mmol/L) defines hypercalcemia; levels ≥14 mg/dL (3.5 mmol/L) constitute severe, life-threatening hypercalcemia. Ionized calcium (normal 1.15-1.35 mmol/L) is more accurate in hypoalbuminemia or acid-base disorders and should be measured when available.

Intact parathyroid hormone (PTH) is the critical branching point. In hypercalcemia of malignancy (HCM), PTH is suppressed (<20 pg/mL) due to negative feedback from the elevated calcium. A normal or elevated PTH points to primary hyperparathyroidism (PHPT) or familial hypocalciuric hypercalcemia (FHH).

Parathyroid hormone-related protein (PTHrP) is the gold-standard test for humoral HCM, the most common subtype. PTHrP is elevated in ~80% of HCM cases, particularly in squamous cell carcinomas (lung, head and neck), renal cell carcinoma , and breast cancer ^[1]B2a. A serum PTHrP level >2.0 pmol/L in the setting of suppressed PTH and hypercalcemia confirms humoral HCM.

Vitamin D metabolites help identify less common subtypes:

• 1,25-dihydroxyvitamin D (calcitriol) is elevated in lymphoma and granulomatous diseases (e.g., sarcoidosis) due to extrarenal 1α-hydroxylase activity.
• 25-hydroxyvitamin D is measured to exclude vitamin D intoxication (rare cause of hypercalcemia).

Urine calcium (24-hour or spot calcium-to-creatinine ratio) distinguishes HCM from FHH. In HCM, urine calcium is elevated (fractional excretion of calcium >0.01); in FHH, it is low (<0.01) due to defective calcium sensing in the renal tubule.

Gold-Standard Diagnostic Approach

The serum PTHrP level is the single most specific test for humoral HCM, which accounts for the majority of cases. When PTHrP is elevated with suppressed PTH, the diagnosis is confirmed without need for further endocrine testing. However, a negative PTHrP does not exclude HCM, osteolytic or vitamin D-mediated subtypes require additional workup.

Diagnostic Algorithm

Step 1: Confirm hypercalcemia with corrected or ionized calcium. Step 2: Measure intact PTH. If suppressed, proceed to PTHrP, 1,25(OH)₂D, 25(OH)D, and urine calcium. Step 3: Elevated PTHrP → humoral HCM. Normal PTHrP with elevated 1,25(OH)₂D → vitamin D-mediated. Normal PTHrP and normal 1,25(OH)₂D → osteolytic HCM (evaluate for bone metastases or myeloma). If PTH is not suppressed, evaluate for PHPT (high urine calcium, elevated PTH) or FHH (low urine calcium, family history, consider CASR mutation testing).

Differential Diagnosis

• Primary hyperparathyroidism: Elevated PTH, high urine calcium, often asymptomatic or mild hypercalcemia. Parathyroid adenoma is the most common cause ^[28]C4.
• Familial hypocalciuric hypercalcemia: Low urine calcium, mildly elevated PTH, benign course. Genetic testing for CASR mutation confirms.
• Vitamin D intoxication: History of high-dose supplementation, elevated 25(OH)D >150 ng/mL.
• Granulomatous diseases: Elevated 1,25(OH)₂D, suppressed PTH, normal PTHrP. Chest imaging and biopsy may reveal sarcoidosis or tuberculosis.
• Medications: Thiazide diuretics, lithium, teriparatide can cause hypercalcemia with elevated or inappropriately normal PTH.

Imaging

Once HCM is confirmed, imaging to identify the underlying malignancy is essential. CT chest, abdomen, and pelvis is the first-line modality to detect solid tumors (lung, renal, breast, head and neck). 18F-FDG PET/CT is more sensitive for occult malignancies and lymphoma. Skeletal survey or whole-body MRI is indicated for multiple myeloma. Imaging is covered in detail in the Antineoplastic Therapy section.

Biopsy / Histology

Biopsy of the suspected tumor is required for definitive cancer diagnosis and treatment planning. Histologic hallmarks vary by tumor type; immunohistochemistry for PTHrP may be performed but is not routinely needed for diagnosis.

Controversies and Guideline Disagreement

Pearl: The single most important branching point in the diagnostic algorithm is the intact PTH level, a suppressed PTH (<20 pg/mL) in the setting of hypercalcemia is virtually diagnostic of HCM and should immediately prompt measurement of PTHrP, 1,25(OH)₂D, and urine calcium to pinpoint the subtype and guide targeted therapy.

Once the diagnosis of hypercalcemia of malignancy is confirmed and severity assessed, treatment should be initiated without delay. The Endocrine Society Clinical Practice Guideline (2023) provides a structured framework for acute management , emphasizing rapid correction of calcium levels while addressing the underlying malignancy ^[40]A1c. The following stepwise protocol integrates the guideline's recommendations with available evidence.

Step 1: Initial Assessment and Severity Classification

Classify severity based on corrected serum calcium and symptom burden. Severe hypercalcemia is typically defined by marked elevation of corrected calcium accompanied by neurologic, cardiac, or renal symptoms (e.g., confusion, lethargy, ECG changes, acute kidney injury). Patients with severe or symptomatic hypercalcemia require urgent intervention and often ICU-level monitoring. The guideline does not specify a numeric threshold but emphasizes clinical judgment ^[40]A1c.

Step 2: Intravenous Hydration

Initiate aggressive intravenous hydration with isotonic saline (e.g., 200-500 mL/h, adjusted for volume status and renal function). The goal is to restore intravascular volume, enhance renal calcium excretion, and correct dehydration common in HCM. Monitor for fluid overload, especially in patients with heart failure or renal impairment. Loop diuretics (e.g., furosemide ) should be reserved for patients who develop volume overload after adequate hydration; routine use is not recommended as it may worsen hypovolemia and electrolyte disturbances ^[31]D5[47]D5.

Step 3: Antiresorptive Therapy

Administer an intravenous bisphosphonate (e.g., zoledronic acid or pamidronate ) or denosumab as first-line therapy. The guideline makes a strong recommendation for either agent ^[40]A1c. A conditional recommendation suggests denosumab over IV bisphosphonate, based on patient values and preferences, though the systematic review found no significant difference in resolution rates between the two ^[41]B2a. For severe HCM, the guideline suggests combining calcitonin with an antiresorptive agent as initial treatment (conditional recommendation) ^[40]A1c.

• Bisphosphonates: Zoledronic acid is typically preferred due to its potency and shorter infusion time. Onset of action is 2-4 days, with maximal effect at 4-7 days. Dose adjustment is required for creatinine clearance <30 mL/min.
• Denosumab: Subcutaneous administration, onset within 1-3 days. No renal dose adjustment needed, making it advantageous in patients with renal impairment. The guideline suggests denosumab as first-line, particularly when rapid onset is desired or bisphosphonates are contraindicated ^[40]A1c.

Step 4: Calcitonin for Rapid Effect

Add subcutaneous or intramuscular calcitonin (e.g., salmon calcitonin) in severe HCM to achieve a more rapid reduction in serum calcium. Calcitonin acts within hours but its effect is modest (typically 0.5-1.0 mg/dL reduction) and often transient due to tachyphylaxis. The guideline conditionally recommends combination therapy with calcitonin and an antiresorptive agent for severe HCM ^[40]A1c. The systematic review found that adding calcitonin did not significantly affect resolution rates or time to normocalcemia, but it may provide early symptomatic relief ^[41]B2a.

Step 5: Glucocorticoids for Vitamin D-Mediated HCM

Consider glucocorticoids (e.g., prednisone 20-40 mg daily) in patients with hypercalcemia driven by elevated calcitriol (e.g., lymphoma, granulomatous diseases). Glucocorticoids reduce intestinal calcium absorption and inhibit calcitriol production. The guideline suggests adding an IV bisphosphonate or denosumab in patients already on glucocorticoids who continue to have severe or symptomatic HCM (conditional recommendation) ^[40]A1c.

Step 6: Monitoring and Transition

Monitor corrected serum calcium daily during acute treatment. Assess renal function, electrolytes, and volume status. Once calcium levels stabilize (typically within 3-5 days), transition to chronic management, including antineoplastic therapy and ongoing antiresorptive treatment as needed. The guideline emphasizes that treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing recurrence ^[40]A1c.

Treatment Failure Protocol

If serum calcium does not improve or worsens after 48-72 hours of first-line therapy:

• Escalate to denosumab if bisphosphonate was used initially (or vice versa). The systematic review reported that two-thirds of patients with refractory/recurrent HCM achieved resolution after denosumab following bisphosphonate therapy ^[41]B2a.
• Consider combination therapy (e.g., bisphosphonate + denosumab) in refractory cases, though evidence is limited.
• Evaluate for hemodialysis in patients with severe, life-threatening hypercalcemia and advanced kidney disease or fluid overload refractory to medical therapy ^[47]D5.

What NOT to Do

• Do not use loop diuretics routinely; reserve for fluid overload only, as they can exacerbate hypovolemia and electrolyte disturbances ^[31]D5.
• Do not rely on calcitonin monotherapy for sustained control; its effect is short-lived and tolerance develops rapidly ^[41]B2a.
• Do not administer bisphosphonates without renal dose adjustment in patients with creatinine clearance <30 mL/min; consider denosumab instead ^[40]A1c.
• Do not delay antineoplastic therapy; definitive treatment of the underlying malignancy is essential for long-term control ^[40]A1c.

Drug Comparison Table

Controversies and Guideline Disagreement

Pearl: For severe hypercalcemia of malignancy, initiate aggressive IV hydration and an antiresorptive agent (denosumab or IV bisphosphonate) immediately; add calcitonin for rapid effect but do not rely on it alone, and escalate to denosumab if bisphosphonate fails (two-thirds of refractory patients respond) ^{[40]A1c[41]B2a}.

When hypercalcemia persists or recurs despite initial intravenous bisphosphonate therapy, the patient is considered to have refractory or recurrent hypercalcemia of malignancy ^[41]B2a. The Endocrine Society Clinical Practice Guideline (2023) provides a conditional recommendation, based on low certainty evidence, for the use of denosumab in this setting ^{[40]A1c[42]D5}. The following stepwise approach integrates the available evidence.

Step 1: Confirm Refractory Status

• Verify that serum calcium remains elevated (e.g., corrected calcium >10.5 mg/dL) or has recurred within days to weeks of initial therapy.
• Reassess volume status, renal function, and tumor progression. Ongoing malignancy drives refractoriness, and antineoplastic therapy should be optimized concurrently ^[40]A1c.

Step 2: Initiate Denosumab

• Administer subcutaneous denosumab (dose per label) ^{[40]A1c[42]D5}. The guideline suggests denosumab over an intravenous bisphosphonate for patients with refractory/recurrent hypercalcemia after prior bisphosphonate treatment (conditional recommendation) ^[40]A1c.
• In a systematic review, two-thirds of patients with refractory/recurrent hypercalcemia who received denosumab following bisphosphonate therapy achieved resolution of hypercalcemia ^[41]B2a.
• Denosumab is also preferred for prevention of hypercalcemia in patients with bone metastases; it delayed time to first on-study hypercalcemia (HR 0.63, 95% CI 0.41-0.98) compared with zoledronic acid in a pooled analysis of phase III trials ^[49]A1a.

Step 3: Re-treatment with Bisphosphonate (If Denosumab Unavailable or Contraindicated)

• If denosumab is not accessible or contraindicated (e.g., severe hypocalcemia risk, prior allergy), re-treatment with an intravenous bisphosphonate (e.g., zoledronic acid or pamidronate) may be considered, though direct evidence for this strategy in refractory disease is lacking ^[40]A1c. The guideline explicitly recommends denosumab over bisphosphonates in this scenario ^[40]A1c.

Step 4: Consider Rebound Hypercalcemia (If Prior Denosumab Was Used)

• If denosumab was recently discontinued, rebound hypercalcemia can occur 4 to 9 months after cessation in adults ^[27]C4. This non-PTH-dependent hypercalcemia typically responds to re-administration of denosumab or a bisphosphonate ^[27]C4. In patients with advanced malignancy, rebound hypercalcemia may mimic skeletal metastases, so awareness is important ^[27]C4.

Step 5: Optimize Antineoplastic Therapy

• The guideline emphasizes that treatment of the underlying malignancy is instrumental for controlling hypercalcemia and preventing recurrence ^[40]A1c. For refractory cases, collaboration with oncology to adjust cancer-directed therapy is essential.

Therapies Not Supported by Current Evidence

• Addition of calcitonin to bisphosphonate or denosumab did not affect resolution of hypercalcemia, time to normocalcemia, or development of hypocalcemia in the systematic review ^[41]B2a. Routine use for refractory disease is not recommended.
• Hemodialysis is not discussed in the reviewed evidence; it is not addressed in the Endocrine Society guideline ^[40]A1c.
• Routine loop diuretic use for calciuresis is not supported by the guideline; the risk of hypovolemia and acute kidney injury outweighs potential benefit ^[40]A1c.

Table: Evidence for Interventions in Refractory Hypercalcemia

Pearl: For refractory hypercalcemia of malignancy after bisphosphonate failure, denosumab is the guideline-preferred agent, with two-thirds of patients achieving resolution; adding calcitonin does not improve outcomes, and optimizing antineoplastic therapy remains the cornerstone of durable control ^{[40]A1c[41]B2a[42]D5}.

Once acute hypercalcemia has been controlled, the cornerstone of long-term management is treatment of the underlying malignancy and prevention of recurrence. The Endocrine Society 2023 guideline emphasizes that treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing its recurrence ^[40]A1c. Antineoplastic therapy, whether systemic chemotherapy, targeted therapy, immunotherapy, radiation, or surgery, directly targets the tumor-driven mechanisms that sustain hypercalcemia, whether humoral (PTHrP), osteolytic, or vitamin D-mediated. The specific regimen depends on tumor histology and stage, and its selection is beyond the scope of this section, but the principle is clear: without effective anti-cancer treatment, antiresorptive agents alone will not durably suppress calcium levels.

Prophylactic Use of Bone-Modifying Agents

For patients with bone metastases from solid tumors (especially lung, breast, prostate, and multiple myeloma ), prophylactic use of intravenous bisphosphonates or denosumab reduces the incidence of skeletal-related events (SREs), including hypercalcemia of malignancy. A network meta-analysis of 131 randomized controlled trials in patients with lung cancer and bone metastases found that denosumab was ranked above zoledronic acid for overall survival (mean +3.3 months, 95% CI 0.3-6.3) and time to SRE (mean +9.1 SRE-free months, 95% CI 6.7-11.5) ^[9]A1a. Both agents reduced the incidence of SREs compared with no treatment (denosumab RR 0.54, 95% CI 0.33-0.87; zoledronic acid RR 0.56, 95% CI 0.46-0.67) ^[9]A1a. These data support initiating bone-modifying therapy at the time of diagnosis of bone metastases and continuing as long as the patient has active bone disease and derives clinical benefit, though the optimal duration is not established by the reviewed evidence.

Monitoring and Calcium Supplementation

Both denosumab and zoledronic acid carry a risk of hypocalcemia , which may be exacerbated by concurrent calcium supplementation. A retrospective cohort study of 271 cancer patients receiving bone-targeting agents reported that the incidence of hypocalcemia was higher with denosumab than with zoledronic acid (5.5% vs. 3.1%; OR 0.55, 95% CI 0.3-1.0) ^[54]C4. Importantly, calcium supplementation reduced the risk of hypocalcemia by 16% (RR 0.84, 95% CI 0.55-1.20) ^[54]C4. The Endocrine Society guideline recommends that all patients receiving denosumab or IV bisphosphonates should have serum calcium, magnesium, and phosphate monitored regularly, and that calcium and vitamin D be supplemented unless hypercalcemia is present ^[40]A1c.

Management of Recurrent Hypercalcemia

Despite optimal antineoplastic therapy and prophylactic bone-modifying agents, hypercalcemia may recur. The Endocrine Society guideline suggests (conditional recommendation) that in adults with refractory/recurrent hypercalcemia despite treatment with bisphosphonate, denosumab should be used ^[40]A1c. For patients with hypercalcemia caused by tumors associated with high calcitriol levels (e.g., lymphomas, granulomatous diseases), the addition of an IV bisphosphonate or denosumab to glucocorticoid therapy is recommended ^[40]A1c. In rare cases of parathyroid carcinoma , calcimimetics (e.g., cinacalcet) or antiresorptive therapy may be used ^[40]A1c.

Table: Comparison of Denosumab and Zoledronic Acid for Prevention of SREs in Bone Metastases

Controversies and Guideline Disagreement

No major guideline disagreements were identified in the reviewed evidence for this topic. The Endocrine Society guideline provides a conditional recommendation preferring denosumab over IV bisphosphonate, based on low-certainty evidence, but acknowledges that both are acceptable options ^[40]A1c.

Pearl: Treat the underlying malignancy to control hypercalcemia durably; for patients with bone metastases, start denosumab or zoledronic acid at diagnosis and ensure calcium/vitamin D supplementation to prevent hypocalcemia ^{[9]A1a[40]A1c[54]C4}.

Effective antineoplastic therapy is the cornerstone of long-term control, but the prognosis of hypercalcemia of malignancy (HCM) remains tied to the underlying cancer and the severity of the metabolic disturbance. The high mortality historically associated with HCM has declined markedly with the introduction of increasingly effective chemotherapeutic agents, yet the syndrome still signals limited survival and substantial morbidity ^{[40]A1c[42]D5}.

Mortality and Survival

In-hospital mortality for severe HCM requiring hemodialysis is approximately 14% in contemporary cohorts, with acute kidney injury complicating nearly 70% of such cases ^[56]C4. For unselected patients with HCM, mortality rates vary widely by cancer type, stage, and response to therapy; the syndrome remains a marker of advanced disease and carries a poor long-term prognosis ^[42]D5. The rapidity of calcium reduction after initial medical therapy may correlate with outcomes, but validated thresholds for prognostication are lacking.

Prognostic Factors

The following table summarizes factors associated with worse outcomes in HCM, drawn from the available evidence.

Role of PTHrP as a Prognostic Marker

Circulating and tumor-derived PTHrP have been studied as prognostic biomarkers. In women with breast cancer, meta-analyses suggest that PTHrP expression is associated with the presence of bone metastases, hypercalcemia, and possibly worse overall survival ^[1]B2a. However, most studies are at high risk of confounding, and the association remains inconclusive for routine clinical use ^[1]B2a.

Recurrence Risk and Long-Term Sequelae

Recurrence of HCM is common unless the primary malignancy is effectively treated. The Endocrine Society guideline emphasizes that "treatment of the primary malignancy is instrumental for controlling hypercalcemia and preventing its recurrence" ^[40]A1c. Long-term survivors of HCM may experience persistent fatigue, pain, and reduced quality of life due to the underlying cancer and its treatment, although specific data on functional outcomes in HCM survivors are sparse ^[42]D5.

Pearl: The most important prognostic factor in hypercalcemia of malignancy is the responsiveness of the underlying cancer to antineoplastic therapy, achieving tumor control is the only intervention that durably prevents recurrence and improves survival.

Management of hypercalcemia of malignancy (HCM) must be tailored when the patient is a child, pregnant, elderly, or immunocompromised. The following subsections outline the key differences in presentation, diagnostic considerations, and treatment modifications for each group.

Pediatrics

HCM is rare in children, with an incidence of 0.4% to 1.0% across different studies ^[30]D5. Unlike adults, pediatric HCM is most frequently associated with hematologic malignancies, particularly acute lymphoblastic leukemia (ALL) ^[30]D5. A distinctive presentation in children with ALL is the combination of severe hypercalcemia, widespread osteolytic lesions, and an absence of circulating blasts on peripheral blood smear ^[3]C4. In one infant with CD19-negative B-ALL, serum calcium was 18 mg/dL and resolved after 2 days of prednisone therapy ^[3]C4.

Antiresorptive therapy with denosumab has been used in pediatric bone disorders, but it carries a specific risk of severe rebound hypercalcemia after discontinuation ^[27]C4. Children appear more prone to this phenomenon because of their higher baseline bone turnover ^[27]C4. Rebound hypercalcemia typically occurs 1.75 to 9 months after the last dose (4-9 months in adults) and can be treated with bisphosphonates or re-administration of denosumab ^[27]C4. In a review of denosumab for aneurysmal bone cysts, multiple cases of severe hypercalcemia were reported in children, leading the authors to recommend reserving denosumab for unresectable lesions ^[48]D5. The effect of denosumab on bone turnover is rapidly reversible, which is a key difference from bisphosphonates and underlies the rebound risk ^[58]D5.

Treatment modifications: In children with ALL-associated HCM, glucocorticoids (e.g., prednisone) are effective and should be initiated promptly. For other causes, bisphosphonates (e.g., pamidronate, zoledronic acid) are used but with dose adjustment for weight and renal function; no specific pediatric doses were reported in the reviewed abstracts. Denosumab should be used with caution, and if discontinued, subsequent antiresorptive therapy (e.g., bisphosphonate) should be considered to prevent rebound hypercalcemia ^[27]C4.

Pregnancy

HCM in pregnancy is rare, and no specific data from the reviewed abstracts address its management. The following recommendations are based on general principles from the available evidence. Bisphosphonates are contraindicated during pregnancy because of potential fetal skeletal toxicity, and denosumab is also contraindicated as it may interfere with fetal bone development. Calcitonin is a short-term option (though not studied in pregnancy for HCM). Acute management should focus on aggressive hydration (with careful monitoring of fluid balance), loop diuretics, and calcitonin if needed. Delivery planning should involve a multidisciplinary team; antineoplastic therapy and definitive treatment of the underlying malignancy are best deferred until after delivery. Breastfeeding is not recommended during antiresorptive therapy, as these agents may be excreted in breast milk.

Elderly

Elderly patients with HCM often have comorbidities that complicate management, particularly chronic kidney disease, heart failure, and polypharmacy. The key modification is the adjustment of bisphosphonate dosing based on renal function. Zoledronic acid is contraindicated in patients with severe renal impairment (per standard prescribing, although the specific cutoff was not reported in the reviewed abstracts). Denosumab may present a safer profile for patients with renal impairment because it is not cleared renally ^[57]D5. However, elderly patients are at increased risk for hypocalcemia with denosumab, and serum calcium should be monitored closely after each dose. Osteonecrosis of the jaw is a rare but serious adverse effect of both bisphosphonates and denosumab, and a dental examination should be performed before initiating therapy when possible. The choice of antiresorptive agent should balance the need for renal safety and the risk of hypocalcemia.

Immunocompromised

Evidence for HCM management in immunocompromised populations (e.g., HIV, transplant recipients, patients on immunosuppressive therapy) is limited. The general principles of acute hydration, bisphosphonates, and denosumab apply. Denosumab may be preferred in patients with renal impairment, which is common in transplant recipients ^[57]D5. Patients should be monitored for infections, especially if glucocorticoids are used. No specific dose modifications for immunocompromised status were reported in the reviewed abstracts. For full dosing recommendations, see the Guidelines and Key Evidence section.

Pearl: In children with HCM, especially those with ALL, check for CD19-negative blasts and consider that hypercalcemia may resolve rapidly with glucocorticoid therapy; be vigilant for rebound hypercalcemia after denosumab discontinuation ^[3]C4[27]C4.

Having reviewed the unique considerations in special populations, the clinician must now turn to the evidence base that shapes current management of hypercalcemia of malignancy (HCM). The landmark trials described below provide the quantitative foundation for the stepwise treatment algorithm, and their findings are directly reflected in contemporary practice guidelines.

Landmark Bisphosphonate Trials

The pivotal trial by Major et al. established zoledronic acid as superior to pamidronate for HCM. In a pooled analysis of 287 patients, a single 4 mg dose of zoledronic acid achieved complete response (normalization of corrected serum calcium) by day 10 in 88.4% of patients, compared with 69.7% for pamidronate 90 mg ^[60]D5. Normalization occurred faster: by day 4, 45.3% of zoledronic acid 4 mg-treated patients had responded versus 33.3% with pamidronate ^[60]D5. Median time to relapse was significantly longer with zoledronic acid, and the lower dose of 4 mg is recommended as initial therapy, with the 8 mg dose reserved for patients requiring retreatment ^[60]D5.

Rosen et al. demonstrated long-term efficacy of zoledronic acid 4 mg every 3 weeks in patients with bone metastases from solid tumors (excluding breast and prostate). At 21 months, fewer patients on zoledronic acid developed an SRE (39% vs 46% placebo), median time to first SRE was prolonged (236 vs 155 days), and the risk of developing an SRE was reduced by 31% (HR 0.693; P = 0.003) ^[66]A1b. These benefits extended to HCM, which was included as a secondary endpoint.

In bladder cancer , Zaghloul et al. randomized 40 patients to zoledronic acid 4 mg monthly or placebo for 6 months. Zoledronic acid reduced the mean SRE incidence (2.05 vs 0.95), prolonged median time to first SRE (16 vs 8 weeks), and decreased the risk of SRE development by 59% (HR 0.413) ^[61]A1b. One-year survival improved from 0% to 36.3% ^[61]A1b.

Denosumab Versus Bisphosphonates

The phase III trial by Martin et al. compared subcutaneous denosumab 120 mg every 4 weeks with intravenous zoledronic acid 4 mg in 2046 breast cancer patients with bone metastases. Denosumab reduced the proportion of patients with an on-study SRE (31% vs 36%, P = 0.006) and prolonged the time to first SRE or HCM by 18% (HR 0.82; 95% CI 0.70-0.95; P = 0.007) ^[65]A1b. Time to first radiation to bone was extended by 26% (HR 0.74; 95% CI 0.59-0.94; P = 0.012) ^[65]A1b. Clinically meaningful improvement in health-related quality of life occurred in 10% more patients receiving denosumab ^[65]A1b.

A network meta-analysis by Bozzo et al. of 131 randomized trials (11,105 patients) with lung cancer and bone metastases ranked denosumab above zoledronic acid for overall survival (mean gain of 3.3 months; 95% CI 0.3-6.3 vs untreated) and time to SRE (mean 9.1 additional SRE-free months; 95% CI 6.7-11.5 vs 4.8 months for zoledronic acid; 95% CI 3.6-6.1) ^[9]A1a. Both agents reduced SRE incidence similarly (relative risk 0.54; 95% CI 0.33-0.87 for denosumab vs 0.56; 95% CI 0.46-0.67 for zoledronic acid) ^[9]A1a.

Comparative Efficacy and Cost-Effectiveness

Rosen et al. compared zoledronic acid 4 mg with pamidronate 90 mg in 1648 patients with multiple myeloma or breast cancer. Zoledronic acid reduced the risk of skeletal complications (including HCM) by an additional 16% (P = 0.030) compared with pamidronate ^[67]A1b. In the breast cancer subgroup, the risk reduction was 20% (P = 0.025) and 30% in those receiving hormonal therapy (P = 0.009) ^[67]A1b.

Cost-effectiveness analyses from Joshi et al. in five European countries found that zoledronic acid was cost-saving or cost-effective in NSCLC patients with bone metastases. Net savings ranged from €113 to €288 per patient in Germany, the United Kingdom, and Portugal; in France and the Netherlands, costs per QALY gained were low (€786 and €8278, respectively) ^[64]B2c.

Guideline Synthesis

The evidence summarized above underpins the current recommendations from oncology societies (ASCO, ESMO, NCCN) for the use of bone-modifying agents in HCM. Key consensus points include:

• First-line therapy for acute HCM: A single dose of intravenous zoledronic acid 4 mg (or 4 mg over 15 minutes) is recommended based on superior complete response rates and faster normalization of calcium compared with pamidronate ^[60]D5. For patients with renal impairment, dose adjustment or alternative agents should be considered.
• Prevention of SREs in patients with bone metastases: Both zoledronic acid (4 mg every 3-4 weeks) and denosumab (120 mg subcutaneously every 4 weeks) are effective, with denosumab showing advantages in overall survival and time to SRE in lung cancer ^[9]A1a and in reducing SREs in breast cancer ^[65]A1b.
• Monitoring: Serum calcium, renal function, and electrolytes should be monitored before and after therapy. Asymptomatic hypocalcemia is the most common drug-related adverse event ^[60]D5.

Table: Key Landmark Trials in Hypercalcemia of Malignancy

These trials collectively demonstrate that both zoledronic acid and denosumab are superior to no treatment, with denosumab offering additional benefits in certain tumor types. The next section will explore how emerging agents and novel therapeutic strategies may further refine the management of HCM.

Pearl: Cost-effectiveness analyses support zoledronic acid as cost-saving or cost-effective across European healthcare systems ^[64]B2c.

Building on these guideline recommendations, several priority areas for future research have emerged. The Endocrine Society Clinical Practice Guideline explicitly identifies current knowledge gaps that should shape research agendas, including the need for prospective trials comparing novel agents and for cost-effectiveness analyses to inform resource allocation ^{[40]A1c[42]D5}.

Emerging Targeted Therapies

Ovarian clear cell adenocarcinoma (OCCA) provides a paradigm for pathway-specific intervention. OCCA tumors overexpress the IL6-STAT3-HIF signaling axis, and expression of PTHLH (the gene encoding PTHrP) explains the frequent hypercalcemia observed in this histotype ^[68]D5. In two patients with chemotherapy-resistant OCCA, treatment with the tyrosine kinase inhibitor sunitinib produced sustained clinical and functional imaging responses, suggesting that targeting the IL6-STAT3-HIF pathway may simultaneously control the malignancy and its paraneoplastic hypercalcemia ^[68]D5. Larger trials of sunitinib and other inhibitors of this pathway in OCCA are warranted ^[68]D5.

Optimizing Established Agents

The network meta-analysis by Bozzo et al. provides the strongest available evidence for ranking bone-modifying agents in lung cancer with skeletal metastases. Denosumab was ranked above zoledronic acid for overall survival (mean gain 3.3 months, 95% CI 0.3-6.3) and for time to skeletal-related event (SRE) (mean additional 9.1 SRE‑free months, 95% CI 6.7-11.5) ^[9]A1a. However, no cost-effectiveness analysis has yet been performed for denosumab versus zoledronic acid in this population, and this represents a critical avenue for future research ^[9]A1a. In Ewing sarcoma, where hypercalcemia is a documented initial SRE, multivariate analysis identified bone metastasis at diagnosis (HR 4.41, p = 0.007), bone marrow invasion (HR 34.08, p < 0.001), and local progression or recurrence (HR 3.98, p = 0.012) as independent risk factors for SREs; the authors call for investigation of the most effective monitoring methods and new preventative therapies ^[11]B2b.

Addressing Knowledge Gaps

The rarity of certain presentations, such as de novo CD19‑negative B‑ALL associated with hypercalcemia and osteolytic lesions, highlights the need for registries and mechanistic studies that can uncover novel pathways driving calcium dysregulation ^[3]C4. The Endocrine Society guideline panel judged that most recommended treatments are probably accessible and feasible but noted variability in costs, resources, and equity impact, all of which require formal health‑systems research ^[40]A1c.

Pearl: The future of HCM management lies in identifying tumor-specific pathways that drive hypercalcemia, such as IL6-STAT3-HIF in OCCA, enabling targeted therapy that addresses both the malignancy and its metabolic complication.